. Comparison of the safety and efficacy of Botulinum toxin type-A and tizanidine in the treatment of cervical dystonia

Relja, Maja; Telarović, Srđana

Pregled bibliografske jedinice broj: 280405

. Comparison of the safety and efficacy of Botulinum toxin type-A and tizanidine in the treatment of cervical dystonia

Relja, Maja; Telarović, Srđana

. Comparison of the safety and efficacy of Botulinum toxin type-A and tizanidine in the treatment of cervical dystonia // Journal of Neurological Sciences, 238 (2005) (podatak o recenziji nije dostupan, kongresno priopcenje, znanstveni)

CROSBI ID: 280405 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
. Comparison of the safety and efficacy of Botulinum toxin type-A and tizanidine in the treatment of cervical dystonia

Autori
Relja, Maja ; Telarović, Srđana

Izvornik
Journal of Neurological Sciences (0022-510X) 238 (2005);

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, kongresno priopcenje, znanstveni

Ključne riječi
BOTOX®; cervical dystonia; tizanidine

Sažetak
Objective: To compare the safety and efficacy of botulinum toxin type-A vs tizanidine in the treatment of cervical dystonia. Patients and Methods:This was a single-blind, randomised, comparative, parallel and two-way crossover study to compare the safety and efficacy of BOTOX® versus tizanidine in the treatment of 42 naï ve idiopathic cervical dystonia patients using the Toronto Western Spasmodic Rating Scale (TWSTRS). Secondary efficacy comprised pain frequency and severity, physician and patient global assessment, and quality of life (QoL). In phase I, Group A received botulinum toxin type-A as BOTOX® (dose range from 100 to 200 U) and Group B received tizanidine as Sirdalud® (dose range from 4 mg to 16 mg) for 6 weeks. In phase II Group A was not treated again but Group B swiched to BOTOX® . Results and Discussion: BOTOX® group showed a greater decrease in TWSTRS score (p<0.0001 at Week 6). Greater decreases in pain frequency and severity were also noted in Group A at Week 6 (decreased frequency, p=0.003 ; decreased severity, p=0.008). Similar reductions were seen in Phase II when tizanidine patients were swiched to BOTOX® . Physician global assessment, patient global assessment and QoL all improved more following BOTOX® treatment compared to tizandine treatment, with statistically significant differences being seen for all analyses at Weeks 2 and 6. Patients also experienced more adverse events following tizanidine treatment (76%) compared to BOTOX® treatment (phase I: 43%, phase II: 40%). Conclusion: BOTOX® treatment provided a significant benefit compared to tizanidine oral medication.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA

Projekti:
0108231

Ustanove:
Medicinski fakultet, Zagreb

Profili:

Srđana Telarović (autor)